{"id":"W2756322479","doi":"10.1136/annrheumdis-2017-eular.1576","title":"OP0201 A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s)","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Medicine; Psoriatic arthritis; Placebo; Psoriasis; Internal medicine; Adalimumab; Ixekizumab; Gastroenterology; Tumor necrosis factor alpha; Clinical endpoint; Surgery; Clinical trial; Immunology; Pathology; Secukinumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001825884,0.001274995,0.00178016,0.0003606279,0.0004134221,0.001263155,0.000750956,0.001421092,0.004145667],"category_scores_gemma":[0.001097225,0.0005878088,0.001848117,0.0003128364,0.0009697611,0.0008822146,0.0003739963,0.004067774,0.0008852109],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000702933,"about_ca_system_score_gemma":0.001503612,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001305265,"about_ca_topic_score_gemma":0.002455338,"domain_scores_codex":[0.9995027,0.0002325008,0.00002343488,0.00006805233,0.00004735488,0.0001259738],"domain_scores_gemma":[0.9990972,0.0002169095,0.0001239735,0.00007027286,0.00006205084,0.0004295557],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8279929,0.04939272,0.005042116,0.0005008028,0.00166518,0.0004139881,0.000206899,0.001387329,0.03164499,0.0003590346,0.004354648,0.07703936],"study_design_scores_gemma":[0.6932943,0.2923519,0.00921736,0.00002127154,0.000434295,0.0002680551,0.0000491442,0.00085514,0.001876902,0.0001851521,0.001420268,0.00002611984],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992939,0.001889318,0.0004893042,0.0006147118,0.0001718222,0.0009694491,0.0009402978,0.00008461969,0.001901359],"genre_scores_gemma":[0.9910917,0.001002748,0.0009393166,0.001258978,0.0002409488,0.0009185849,0.002257075,0.00002761126,0.002263092],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004145667,"threshold_uncertainty_score":0.01386857,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0230903480471805,"score_gpt":0.282034882909017,"score_spread":0.2589445348618364,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}